[go: up one dir, main page]

IN2014MU00916A - - Google Patents

Info

Publication number
IN2014MU00916A
IN2014MU00916A IN916MU2014A IN2014MU00916A IN 2014MU00916 A IN2014MU00916 A IN 2014MU00916A IN 916MU2014 A IN916MU2014 A IN 916MU2014A IN 2014MU00916 A IN2014MU00916 A IN 2014MU00916A
Authority
IN
India
Prior art keywords
pharmaceutical composition
relates
dolutegravir
preparing
treatment
Prior art date
Application number
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to PCT/GB2015/050826 priority Critical patent/WO2015140569A1/en
Priority to IN916MU2014 priority patent/IN2014MU00916A/en
Publication of IN2014MU00916A publication Critical patent/IN2014MU00916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising an integrase inhibitor, and more particularly, relates to a pharmaceutical composition comprising dolutegravir, a process for preparing such pharmaceutical composition, and its use in the treatment of HIV infections.
IN916MU2014 2014-03-20 2015-03-20 IN2014MU00916A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/GB2015/050826 WO2015140569A1 (en) 2014-03-20 2015-03-20 Pharmaceutical composition
IN916MU2014 IN2014MU00916A (en) 2014-03-20 2015-03-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN916MU2014 IN2014MU00916A (en) 2014-03-20 2015-03-20

Publications (1)

Publication Number Publication Date
IN2014MU00916A true IN2014MU00916A (en) 2015-09-25

Family

ID=54143803

Family Applications (1)

Application Number Title Priority Date Filing Date
IN916MU2014 IN2014MU00916A (en) 2014-03-20 2015-03-20

Country Status (2)

Country Link
IN (1) IN2014MU00916A (en)
WO (1) WO2015140569A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011506B2 (en) 2017-06-30 2024-06-18 Viiv Healthcare Company Combination and uses and treatments thereof
GB202009684D0 (en) * 2020-06-26 2020-08-12 Viiv Healthcare Co Formulations
GB202009685D0 (en) * 2020-06-25 2020-08-12 Viiv Healthcare Co Formulations
WO2022044050A1 (en) * 2020-08-28 2022-03-03 Varalakshmi Mummidi Poly hydroxy oligomer coated dolutegravir aquasomes and method thereof
CN114209655B (en) * 2021-12-31 2023-11-28 瑞孚信江苏药业股份有限公司 Preparation method of dolutegravir micropowder
CN114191404B (en) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 Duolavir tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX302718B (en) 2005-04-28 2012-08-27 Smithkline Beecham Corp Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity.
LT3494972T (en) 2010-01-27 2024-03-12 Viiv Healthcare Company Combinations of dolutegravir and lamivudine for the treatment of hiv infection
CN102985072A (en) * 2010-04-20 2013-03-20 希普拉有限公司 Pharmaceutical compositions
NZ607935A (en) * 2010-09-13 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising rifaximin
CA2812505A1 (en) * 2010-10-01 2012-04-05 Cipla Limited Pharmaceutical composition
PL2742051T3 (en) * 2011-09-14 2017-06-30 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
BR112015006558A2 (en) * 2012-10-23 2017-07-04 Cipla Ltd pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition, and method for preventing or treating retrovirus diseases

Also Published As

Publication number Publication date
WO2015140569A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
ZA201708692B (en) Antibacterial compounds
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MA40238A (en) Modulators of toll-like receptors for the treatment of hiv
GB2541571A (en) Pharmaceutical compositions
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2017004808A (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis.
CL2015002897A1 (en) Bace1 inhibitors
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
IN2014MU00303A (en)
EP4218736A3 (en) Compositions comprising 15-hepe
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MX2017003301A (en) Refractory product, batch composition for producing said product, method for producing the product and use of said product.
IN2014MU00916A (en)
MX2017003928A (en) Long acting pharmaceutical compositions.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2017001487A (en) Sofosbuvir in crystalline form and process for its preparation.
MX2020009444A (en) Low dose oral pharmaceutical composition of isotretinoin.
PH12017500602A1 (en) Methods for treating ocular conditions
IN2014CH00840A (en)
FI20165932A7 (en) Immunomodulatory compositions
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
PT3394069T (en) Process for the preparation of hiv integrase inhibitors
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases